Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy

In the current era of immune checkpoint inhibitors (ICI), the role and timing of nephrectomy remains unknown, particularly in cases of residual kidney disease after a major response at metastatic sites. In these cases, the rationale for a delayed nephrectomy is that it might achieve a long-term response. This strategy could allow some patients to discontinue treatment and maintain tumor response. Furthermore, this approach might provide a potentially curative option for patients with metastases that are managed with and responding to ICI. Regarding the results of our first retrospective cohor

Trial Details

NCT ID

NCT06882486

Phase

NA

Sponsor

Institut Paoli-Calmettes

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

• nephrectomy

Locations (sample)

• Marseille, Institut Paoli-calmettes, France|43.29695,5.38107

Key Eligibility Criteria

• Patient aged ≥ 18 years
• Diagnosed with synchronous metastatic kidney cancer
• With primary tumor still in place (no primary cytoreductive nephrectomy)
• Having received systemic ICI immunotherapy-based combination therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →